Numerai’s Harmony Biosciences HRMY Stock Holding History

Numerai’s Portfolio HRMY Stock Details HRMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-6,867	Closed	-$207K	–	403
2024 Q2	$207K	Buy	+6,867	New	+$206K	0.08%	282

Other funds holding HRMY

Valor Management Chicago, Illinois $181M AUM 6.67% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Numerai's HRMY Position: Q3 2024 in Review

Numerai sold out of Harmony Biosciences (HRMY) in Q3 2024, closing a stake of 6,867 shares — an estimated $207K sold.

Numerai first reported a position in HRMY in Q2 2024 and held it in 1 quarter. The position peaked at $207K in Q2 2024. 233 funds tracked by Wall St. Rank hold HRMY as of Q3 2024.

Numerai reported no remaining Harmony Biosciences position as of Q3 2024 after selling out during the quarter.
Numerai sold 6,867 Harmony Biosciences shares in Q3 2024, an estimated $207K.
Numerai first reported a position in Harmony Biosciences in Q2 2024 and held it in 1 quarter.
Numerai's Harmony Biosciences position peaked at $207K in Q2 2024.
233 funds tracked by Wall St. Rank held Harmony Biosciences as of Q3 2024.

Based on Numerai's 13F filing for Q3 2024, filed 14 Nov 2024.